Drug Profile
GM 7050
Latest Information Update: 06 Jun 1995
Price :
$50
*
At a glance
- Originator Glycomed
- Developer Genentech; Glycomed
- Class Anti-inflammatories; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammation
Most Recent Events
- 30 May 1995 New profile
- 30 May 1995 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 30 May 1995 Discontinued-Preclinical for Inflammation in USA (Unknown route)